Find, compare & contact
Bisolvon metabolite viii (Ambroxol) API Manufacturers & Suppliers

Looking for Ambroxol API 18683-91-5?

Description:

Here you will find a list of producers, manufacturers and distributors of Ambroxol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Ambroxol 

Synonyms:

Amboxol , Ambroxol , Ambroxol hcl , Ambroxolum , Bisolvon metabolite vIII , Bromhexine metabolite vIII , Bromhexine-metabolite vIII , Tabcin , Ambroxol hydrochloride  

Cas Number:

18683-91-5 

DrugBank number:

DB06742 

Unique Ingredient Identifier:

200168S0CL

Ambroxol is a type of Mucolytics

Mucolytics are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of respiratory conditions. Mucolytics are specifically designed to alleviate respiratory distress by enhancing the clearance of mucus from the airways.

These APIs work by breaking down the chemical bonds within mucus, reducing its viscosity and promoting its removal from the respiratory tract. By thinning the mucus, mucolytics facilitate easier expectoration and help to relieve congestion and cough associated with respiratory conditions such as chronic bronchitis, asthma, and cystic fibrosis.

One of the commonly used mucolytics is N-acetylcysteine (NAC), which acts as a precursor for the synthesis of glutathione—a powerful antioxidant. Glutathione helps to protect the respiratory system from oxidative stress and inflammation, promoting healthy lung function. NAC's mucolytic properties make it an effective treatment for conditions characterized by excessive mucus production.

Mucolytics can be formulated in various dosage forms, including oral tablets, effervescent granules, and inhalation solutions. The choice of formulation depends on the target condition and the desired mode of administration.

Overall, mucolytics play a crucial role in the management of respiratory disorders by improving mucus clearance and reducing airway obstruction. These pharmaceutical APIs offer relief to patients suffering from respiratory conditions, promoting better breathing and overall quality of life.

Ambroxol (Mucolytics), classified under Respiratory Tract Agents

Respiratory Tract Agents are a vital category of pharmaceutical APIs (Active Pharmaceutical Ingredients) designed to treat respiratory conditions and diseases. These agents are specifically formulated to target the respiratory system, which includes the lungs, airways, and nasal passages. They play a crucial role in managing various respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.

Respiratory Tract Agents encompass a wide range of medications, including bronchodilators, corticosteroids, antihistamines, and mucolytics. Bronchodilators are commonly used to relieve airway constriction and facilitate smooth breathing by relaxing the muscles in the airways. Corticosteroids help reduce inflammation in the respiratory system, alleviating symptoms and preventing exacerbations. Antihistamines work by blocking histamine receptors, thus mitigating allergic reactions that often impact the respiratory tract. Mucolytics aid in loosening and thinning mucus, making it easier to expel from the airways.

These APIs are developed through rigorous research and development processes, ensuring their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers rely on advanced technologies and stringent quality control measures to produce high-quality Respiratory Tract Agents. These APIs are subsequently incorporated into various dosage forms, including inhalers, nasal sprays, nebulizers, and oral medications.

Respiratory Tract Agents are essential in the management of respiratory conditions, providing relief from symptoms, improving lung function, and enhancing the overall quality of life for patients. They are prescribed by healthcare professionals and often used in combination therapies to achieve optimal results. As respiratory disorders continue to affect a significant portion of the global population, the development and availability of effective Respiratory Tract Agents play a vital role in addressing these health challenges and improving patient outcomes.

• Shilpa Medicare Ltd from India, product country of origin India
• Shandong Octagon Chemicals Limited from China, product country of origin China
• SETV Global from India, product country of origin India
• Xi'an ZB Biotech Co., Ltd from China, product country of origin China
• United Pharma Industries Co Ltd from China, product country of origin China
• Cambrex from Italy, product country of origin Unknown
• Shizuoka Coffein Co from Japan, product country of origin Japan
• Dong Wha Pharm from South Korea, product country of origin South Korea
• Alchymars ICM SM from India, product country of origin India
• Bidachem from Italy, product country of origin Italy
• TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
• Ven Petrochem & Pharma from India, product country of origin India
• Aarambh Life Science from India, product country of origin India
• Pen Tsao Chemical Industry from Germany, product country of origin China
• Boehringer Ingelheim from Germany, product country of origin Germany
• Shaoxing Hantai Pharma from China, product country of origin China
• Erregierre from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.